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 Cisplatin down-regulates Apelin expression in HEI-OC1 cells and cochlear hair 
cells. 
 Apelin protects HEI-OC1 cells and cochlear hair cells from cisplatin-induced 
injury in vitro. 
 Apelin attenuates cisplatin-induced ROS and apoptosis in HEI-OC1 cells and 




Apelin, a specific endogenous ligand of the G protein-coupled receptor APJ, 
suppresses oxidative stress and apoptosis in vitro and in vivo. The current study 
explored whether Apelin protects against toxicity induced by the anticancer drug 
cisplatin in vitro, and the possible mechanisms that underlie this protective effect. The 
results showed that Apelin was expressed in the mouse auditory cell line HEI-OC1 
and in cochlear hair cells (HCs) and was significantly downregulated by cisplatin, 
whereas pre-treatment with exogenous Apelin significantly reduced cisplatin-induced 
apoptosis, and thus protected HEI-OC1 cells and cochlear HCs from cisplatin-induced 
injury. Furthermore, Apelin reduced reactive oxygen species (ROS) generation, 
rescued mitochondrial membrane potential disruption, inhibited JNK signaling and 
attenuated the expression of pro-apoptotic factors in HEI-OC1 cells and in cochlear 











otoprotective agent for the prevention of cisplatin-induced ototoxicity.  
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 Cisplatin is an anti-tumor drug commonly used in the treatment of clinical 
tumors due to its broad and efficient anti-tumor spectrum. However, the drug has 
ototoxic side effects, most seriously permanent hearing loss, for which no effective 
treatments are currently available[1]. It is widely accepted that cisplatin causes 
apoptosis of cochlear hair cells (HCs), causing ototoxicity to occur primarily in the 
cochlea in the inner ear[2,3]. Recent studies showed that excessive ROS production and 
mitochondrial dysfunction induced by cisplatin are key contributors to apoptosis in 
the cochlea[4]. In particular, excessive ROS production depletes the antioxidant 
defense mechanisms of cochlear HCs, disrupts mitochondrial function, interferes with 
cellular signaling pathways and triggers apoptotic cell death by activating caspase 
enzymes. However, the specific pathological mechanism(s) of cisplatin-induced 
ototoxicity remains unclear[5]. Inhibiting excessive ROS generation and apoptotic 
processes could be a strategy to prevent cisplatin-induced ototoxicity.  
The bioactive peptide Apelin is a ligand of the G-protein coupled receptor APJ 
and is a key regulator of oxidative stress and apoptosis. The Apelin gene encodes an 











several C-terminal deletion variants including Apelin-12, Apelin-13, Apelin-17 and 
Apelin-36[6]. Apelin-13 is the major subtype that has the strongest biological activity, 
and is the variant used in the current study. Apelin is widely expressed in several 
tissues and organs such as heart, lung, brain, kidney, liver, blood vessels, 
gastrointestinal tract and adipose tissue[7,8]. Apelin exhibits protective effects in 
diseases that involve cellular injury due to its anti-oxidatitive and anti-apoptotic 
roles[9,10]. Apelin promotes the activity of the mitochondrial enzymes superoxide 
dismutase, catalase and glutathione peroxidase and reduces the formation of hydroxyl 
radicals and malondialdehyde, thus reducing renal ischemia/reperfusion damage[11]. 
[Pyr1]-apelin-13 reduces myocardial damage by decreasing oxidative injury in a rat 
model of myocardial infarction[12]. Apelin inhibits ROS-mediated DNA damage and 
up-regulates the MAPKs/Akt pathway to attenuate cisplatin-induced myocardial 
toxicity[13]. The peptide regulates apoptosis in several cell types and so has been 
suggested to be a potential target for therapeutics that could prevent apoptosis in 
certain diseases. In addition, Apelin has neuroprotective effects, which result from 
inhibition of apoptosis in ischemia-induced brain damage, intracerebral hemorrhage, 
Alzheimer's disease, and Parkinson’s disease[10,14-16]. Moreover, Apelin inhibits 
endoplasmic reticulum stress-induced apoptosis mediated by FoxO1, thus alleviating 
ischemia/reperfusion injury[17].  
Mounting evidence shows that Apelin has anti-oxidative and anti-apoptotic roles 
in different cell types[11,12,15,18,19], but the role of Apelin in the cells of the inner ear has 











cisplatin-induced auditory cell damage, and the possible mechanism(s) underlying this 
process. 
2. Materials and methods 
2.1 HEI-OC1 culture and treatment  
HEI-OC1 cells were cultured as described previously[20]. Cisplatin (P4394, Sigma-
Aldrich) was used at a concentration of 30 μM because this concentration caused 
apoptosis and injury in HEI-OC1 cells and HCs. HEI-OC1 cells were pretreated with 
varying concentrations of Apelin (057-18, Phoenix Pharmaceuticals) for 2 h followed 
by cisplatin treatment. Cells were then used for the designated experiments. 
2.2 Cochlear organ culture and treatment 
C57BL/6 mice were sacrificed at four days old and the cochlear organs were dissected 
out quickly in cold Hank’s buffer and pasted on small round coverslips. The cochlear 
explants were cultured in DMEM/F12 medium containing 10% fetal bovine serum. 
They were then treated with 30 μM cisplatin for 24 h, or pretreated with 10 nM 
Apelin for 2 h followed by cisplatin treatment for another 24 h. All animal 
experiments were performed according to the ordinance and ethical requirements of 
the Animal Care Committee of Jining Medical University.  
2.3 Immunofluorescence staining 
All specimens were fixed with 4% paraformaldehyde (PFA), washed with PBS, 
permeabilized with 1% Triton-X 100 in PBS for 10 min, blocked with 1% BSA for 1 
h at room temperature, and then incubated with primary antibodies overnight at 4℃. 











(1:1000, D9542, Sigma) for 1 h in the dark at room temperature. The specimens were 
analyzed using a confocal microscope (LEICA TCS SP8). The primary antibodies 
used in immunofluorescence staining were as the follows: rabbit anti-Apelin (1:800, 
ab59469, Abcam), rabbit anti-APJ (1:800, ab214369, Abcam), mouse anti-myosin7α 
(1:1000, DSHB), and rabbit anti-cleaved caspase-3 (1:1000, 9664S, Cell Signaling 
Technology). 
2.5 Cell viability assay 
HEI-OC1 cells were seeded at a density of 8×103 cells/well in a 96-well plate and 
treated with 30 μM cisplatin for 24 h, or treated with 0.1 nM, 1 nM, 10 nM or 100 nM 
Apelin for 24 h, or pre-treated with Apelin for 2 h followed by cisplatin treatment for 
another 24 h. After the designate treatments, 10 μl CCK-8 (96992, Sigma-Aldrich) 
was added to each well and incubated for 2 h at 33℃. Cell viabilities were analyzed 
with an ELISA reader (Multiskan MK3). The cell viability of control group was taken 
as 100%. Three independent experiments were performed. 
2.6 Protein electrophoresis separation and immunoblotting  
Cells and cochlear explants were collected and lysed in RIPA buffer (P0013B, 
Beyotime Biotechnology) containing 1% protease inhibitor cocktail ( P8340-1ML, 
Merck KGaA) for 30 min on ice. Equal amounts of proteins were loaded on a sodium 
dodecyl sulfate polyacrylamide gel and separated by electrophoresis. Proteins were 
transferred to polyvinylidene fluoride membranes (PVDF; Millipore). PVDF 
membranes were blocked with 5 % milk in TBS buffer containing 0.05 % Tween20 











overnight at 4 °C followed by incubation with secondary antibodies for 1 h at room 
temperature. Protein signals were detected using an enhanced chemiluminescence 
(ECL) kit (WBULS0100, Millipore) and analyzed using ImageJ software (Broken 
Symmetry Software). The primary antibodies used were as follows; rabbit anti-
cleaved caspase-3 (1:1000, 9664S, Cell Signaling Technology), mouse anti-cleaved 
caspase-9 (1:1000, Asp353, Cell Signaling Technology), rabbit anti-bax (1:1000, 
ab32503, Abcam), rabbit anti-phospho-JNK (1:500, 9251S, Cell Signaling 
Technology), mouse anti-total-JNK (1:1000, 9252S, Cell Signaling Technology), 
mouse anti-GAPDH (1:2000, TA-08, ZSGB-BIO), and mouse anti-β-actin (1:2000, 
TA-09, ZSGB-BIO). 
2.7 TUNEL staining 
A TUNEL kit (C10617, Life technologies) was used to detect apoptotic cells 
according to the manufacturer’s protocols. First, samples were fixed with 4% PFA, 
permeabilized with 0.1% Triton X-100 in PBS for 20 min at room temperature, 
incubated with TUNEL working solution for 1 h, and shielded from light at 37 °C. 
The nuclei were stained by DAPI for 30 min. The specimens were analyzed using a 
confocal laser microscope (LEICA TCS SP8). 
2.8 Flow cytometry 
An Annexin V-FITC Apoptosis Kit (BD Biosciences, CA) was used to detect 
apoptotic cells according to the manufacturer’s protocols. HEI-OC1 cells were 
collected into 10 ml centrifuge tubes, centrifuged at 1000g, and then resuspended in 











suspension and mixed gently, after which the cells were incubated at room 
temperature for 15 min in the dark. Samples were immediately subjected to flow 
cytometry using a FACS Calibur system (BD Biosciences) and the data were analyzed 
using Flow Jo7.6 software. Experiments were repeated three times. 
2.9 ROS detection 
HEI-OC1 cells and cochlear explants were incubated with 10 μM DCFH-DA (D6883, 
Sigma Technologies) or 5 μM Mitosox-red probes (1771410, Life Technologies) in 
serum-free DMEM for 30 min in the dark. After washing with PBS, the fluorescence 
signal was detected using a fluorescence microscope or FACS Calibur system. 
2.10 Mitochondrial membrane potential detection 
HEI-OC1 cells and cochlear explants were incubated with 1 μM Rhodamine 123 
(C2007, Beyotime Biotechnology) in PBS for 30 min at 37°C in an incubator. They 
were then washed with PBS and the fluorescence signals were detected using a 
fluorescent microscope. 
2.11 Statistical analysis 
Data were presented as mean ± SD, and analyzed by GraphPad Prism 6 software 
using Student's t-test or one-way analysis of variance (ANOVA). P < 0.05 was 

















3.1 Apelin and APJ are expressed in HEI-OC1 cells and mouse cochlear HCs  
We first investigated whether auditory cells express Apelin and APJ, using HEI-OC1 
cells, a conditionally immortalized cochlear cell line derived from mouse organ of 
Corti, and HCs labeled with Myosin7α (a specific marker of HCs) in cultured 
cochlear explants. Results showed that Apelin and APJ were expressed in HEI-OC1 
cells and HCs (Fig. 1A-D). In addition, the expression of APJ was significantly higher 
in outer hair cells (OHC) than in inner hair cells (IHC). However, there was no 
marked difference in the expression levels of Apelin in IHCs and OHCs. These results 
suggested that the Apelin–APJ axis might play a potential role in auditory cells, 
especially in OHCs, and provided a basis for further study. 
(Fig.1) 
3.2 Endogenous Apelin is down-regulated by cisplatin in HEI-OC1 cells and 
mouse cochlear HCs. 
Endogenous Apelin expression was examined in HEI-OC1 cells at 0 h, 6 h, 12 h and 
24 h after treatment with 30 μM cisplatin. Immunofluorescence staining showed that 
Apelin was downregulated by cisplatin in a time-dependent manner. Apelin 
expression was significantly decreased at 6 h and was lowest at 24 h (Fig. 2A). Down-
regulation of Apelin by cisplatin was confirmed by western blot analysis (Fig. 2B). 
The expression of Apelin was also detected in HCs treated with or without cisplatin 











lower in surviving OHCs and IHCs treated with cisplatin for 24 h than in the control 
group (Fig. 2C). Down-regulation of Apelin was confirmed by western blot analysis 
in cochlear explants treated with cisplatin for 24 h (Fig. 2D). 
(Fig.2) 
3.3 Apelin protects HEI-OC1 and cochlear HCs from cisplatin-induced injury. 
Data from the CCK-8 assay showed that Apelin alone had no effect on HEI-OC1 cell 
viability, but significantly increased the viability of HEI-OC1 cells treated with 
cisplatin in a concentration-dependent manner. The protective effect of 10 nM Apelin 
was greater than that of 1 nM Apelin in cisplatin-injured cells, but was not 
significantly different from that of 100 nM cisplatin. Therefore, 10 nM was selected 
for subsequent experiments (Fig. 3A). As shown in Fig. 3B, Apelin-treated and 
control OHCs (three rows) and IHCs (one row) were of normal shape and were 
arranged neatly. Conversely, cisplatin treatment resulted in degeneration and a 
disordered arrangement of HCs. This was accompanied by loss of HCs, which 
appeared aggravated gradually from apex turns to basal turns. Apelin pretreatment 
significantly alleviated cisplatin-induced HC damage (Fig. 3B). Total HC counts 
(including IHCs and OHCs) showed that HC loss was more severe in basal and 
middle turns of cisplatin-treated cochlear explants than that in control explants, 
whereas Apelin pre-treatment significantly attenuated cisplatin-induced HCs loss in 
the basal and middle turns (Fig. 3C-E). However, the total number of HCs in the apex 
turns had no significant difference between cisplatin- and Apelin plus cisplatin-treated 











HEI-C1 cells and HCs of cochlear explants, especially in the middle and basal turns.  
(Fig.3) 
3.4 Apelin prevents cisplatin-induced apoptosis in HEI-OC1 cells. 
Apoptotic cells were examined using flow cytometry and TUNEL staining. Flow 
cytometry results showed that the proportion of apoptotic cells was significantly 
higher in the cisplatin-treated group than in the control group; this effect was 
decreased by 10nM Apelin pretreatment (Fig. 4A-B). The number of TUNEL-positive 
stained apoptotic cells was significantly higher in cisplatin-treated group, but was 
significantly decreased by 10nM Apelin pretreatment (Fig. 4C-D). These results 
indicated that Apelin prevented cisplatin-induced apoptosis in HEI-OC1 cells. 
(Fig.4) 
3.5 Apelin alleviates cisplatin-induced apoptosis in HCs of cochlear explants. 
The number of TUNEL-positive stained cells was significantly higher in cochlear 
explants treated with cisplatin than that in the control group; Apelin pretreatment 
significantly decreased the number of stained cells (Fig. 5A-B). Furthermore, the 
number of cisplatin-induced apoptotic HCs co-stained by TUNEL and myosin7α 
was also significantly decreased by Apelin pretreatment (Fig. 5A, 5C). Similarly, 
Apelin pretreatment significantly decreased the number of cleaved caspase3-positive 
stained cells as well as the number of cleaved caspase-3/Myosin7a co-stained cells in 
cochleae treated with cisplatin (Fig. 5D-F). These results implied that Apelin 












3.6 Apelin diminishes cisplatin-induced ROS and disruption of mitochondrial 
membrane potential in HEI-OC1 cells and cochlear explants. 
DCFH-DA and Mitosox-red probes were used to monitor ROS generation in HEI-
OC1 cells and cochlear explants treated with cisplatin or cisplatin combined with 
Apelin. Immunofluorescence and flow cytometry results showed that fluorescence 
signals of DCFH-DA and Mitosox-red were highest in HEI-OC1 cells treated with 
cisplatin, and were lower in cells pre-treatment with Apelin, indicating that Apelin 
suppressed cisplatin-induced ROS generation in HEI-OC1 cells (Fig. 6A-D). 
Similarly, Apelin also significantly reduced the cisplatin-induced increase in DCFH-
DA and Mitosox-red fluorescence signals in cochlear explants (Fig. 6E-F). Taken 
together, these results indicate that Apelin inhibited cisplatin-induced excessive ROS 
production, which is known to potentiate cisplatin-induced ototoxicity. In addition, a 
Rhodamine 123 probe was used to detect the mitochondrial membrane potential of 
HEI-OC1 cells and cochlear cells. Rhodamine 123 fluorescence was higher in HEI-
OC1 cells and cochlear explants treated with cisplatin than in control cells, but was 
reduced by Apelin pre-treatment (Fig. 6G-H). These results indicate that Apelin 
prevented the disruption in mitochondrial membrane potential caused by cisplatin in 
HEI-OC1 cells and cochlear explants in vitro.  
(Fig.6) 
3.7 Apelin inhibits cisplatin-induced activation of JNK signaling and caspase-
dependent apoptosis in HEI- OC1 cells and cochlear explants. 











induced toxicity in vitro, JNK signaling and the levels of apoptotic-related factors, 
including cleaved caspase-3, cleaved caspase-9 and bax, were examined. We found 
that Apelin pre-treatment significantly reduced the cisplatin-induced increase in p-
JNK protein levels (Fig. 7A-B) and reduced the cisplatin-induced increase in cleaved 
caspase-3, cleaved caspase-9 and bax levels in HEI-OC1 cells (Fig. 7C-F). In 
addition, the expression of p-JNK, cleaved caspase-3, cleaved caspase-9 and bax was 
assayed by western blot in cochlear explants treated with cisplatin or cisplatin 
combined with Apelin (Fig. 7H-L). These results indicated that Apelin protect against 
cisplatin-induced toxicity through inhibition of JNK signaling and caspase-dependent 

























 Prior to this study it was unknown whether the widely expressed bioactive 
peptide Apelin and its cognate receptor are expressed in auditory cells. We initially 
showed that Apelin and APJ are expressed in HEI-OC1 cells and cochlear HCs from 
mice. This result widens our knowledge of expression range of Apelin and APJ in 
mammals, and provides a foundation for further evaluation of the potential role of 
Apelin in cisplatin-induced ototoxicity. 
Apelin has protective roles in, and is down-regulated in several diseases such as 
ischemia-reperfusion injury, neurodegenerative diseases, metabolic disorders and 
aging[21,22]. In this study, endogenous Apelin was down-regulated by cisplatin in HEI-
OC1 cells and cochlear explants in vitro. These results indicated that down-regulation 
of Apelin expression may be related to cisplatin-induced damage to inner ear cells. 
We hypothesized that exogenous Apelin pretreatment could alleviate cisplatin-induced 
damage. Indeed, exogenous Apelin protected HEI-OC1 cells and HCs from cisplatin-
induced injury, while Apelin itself had no cytotoxic effect on these cells. Moreover, 
the protective effect of Apelin was greater in HCs in basal and middle turns than in 
apex turns. 
It is well established that cisplatin-induced apoptosis eventually leads to HC loss 
and hearing impairment[3]. In this work, we found that exogenous Apelin pretreatment 
alleviated cisplatin-induced apoptosis in HEI-OC1 cells and HCs in vitro, implying 











These results are consistent with studies demonstrating that Apelin has anti-apoptotic 
effects in other diseases such as ischemia-induced brain damage, intracerebral 
hemorrhage, Alzheimer’s disease, and Parkinson’s disease[14,15,17,23]. Taken together, 
our results suggest that Apelin provides otoprotection against cisplatin-induced injury 
in vitro by inhibiting apoptosis. 
Exposure to high doses of cisplatin leads to excessive ROS accumulation in 
cochlea[24]. Excessive ROS production can cause mitochondrial dysfunction in HCs, 
leading to apoptosis[25]. Application of antioxidants is an effective protective strategy 
to reduce cisplatin-induced ototoxicity[26,27]. Apelin improves the function of 
mitochondria and decreases ROS production in oxidative stress-induced apoptosis. In 
addition, Apelin prevents ROS-dependent hypertrophy by enhancing antioxidant 
activity in the heart, and structural analogs of Apelin inhibit mitochondria-derived 
ROS production and apoptosis in cortical neurons[9,14]. Apelin also attenuated 
oxidative stress in human adipocytes[28]. In this work, we showed that Apelin 
significantly reduced cisplatin-induced increases in intracellular ROS in both HEI-
OC1 cells and cochlear explants. This observation is consistent with a report 
demonstrating Apelin-13 protects hair cell-like cells treated with by hydrogen 
peroxide (H2O2) from oxidative stress-induced apoptosis
[29]. Therefore, we suggest 
that the otoprotective effect of Apelin is closely associated with its ability to inhibit 
excessive ROS production, which is known to potentiate cisplatin-induced apoptosis. 
Excessive ROS production is associated with disruption of mitochondrial membrane 











mitochondrial dysfunction[30]. The dysfunction of mitochondria in turn potentiates 
excessive ROS generation and apoptosis. In this study, Apelin significantly extenuated 
the cisplatin-induced loss of mitochondrial membrane potential in HEI-OC1 and 
cochlear explants, implying that Apelin rescued mitochondrial dysfunction.  
ROS–JNK signaling is involved in cochlear cell apoptosis induced by a variety 
of stimuli, and might be a promising therapeutic target for treating hearing 
impairment[31]. Our results showed that Apelin inhibited cisplatin-induced activation 
of JNK signaling both in HEI-OC1 cells and cochlear explants, implying that Apelin 
might alleviate cisplatin-induced apoptosis by inhibiting JNK signaling. It is well 
known that bax, caspase-9, and caspase-3 are involved in the apoptotic pathway. Bax 
increases mitochondrial membrane permeability, leading to activation of caspase-9 
and caspase-3, thereby initiating activation of apoptotic pathways. In this work, 
Apelin significantly reduced the cisplatin-induced increase in expression of pro-
apoptotic factors including bax, cleaved caspase-9 and cleaved caspase-3 in HEI-OC1 
cells and cochlear explants in vitro. These results indicate that Apelin may prevent 
cisplatin-induced ototoxicity by inhibiting the caspase-dependent apoptotic pathway. 
In conclusion, we have shown that that Apelin protects against cisplatin-induced 
toxicity by reducing ROS generation, inhibiting JNK signaling, and attenuating 
apoptosis in vitro. Our findings indicate that Apelin could be an effective agent for 
preventing cisplatin-induced damage in auditory cells. Because this study was 
performed in vitro, further studies will be required to determine whether Apelin 
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Figure 1 Apelin and APJ are expressed in HEI-OC1 cell and mouse cochlear HCs 
(A-B) Immunofluorescence staining of Apelin (red staining) and APJ (red staining) 
expression in HEI-OC1 cells. (C-D) Immunofluorescence staining of Apelin (red 
staining) and APJ (red staining) expression in cochlear HCs labeled with Myosin7a 















Figure 2 Endogenous Apelin expression is downregulated by cisplatin in HEI-
OC1 cells and mouse cochlear HCs in vitro 











expression in HEI-OC1 cells exposed to 30 μM cisplatin for various times. 
(B) Apelin expression was assayed by western blot in HEI-OC1 cells exposed 
to 30 μM cisplatin for various times. (C) Immunofluorescence staining of 
Apelin (red staining) expression in HCs labeled by Myosin7α (green staining) 
in middle turns of cochlear explants treated with 30 μM cisplatin for 24 h. (D) 
Apelin expression was assayed by western blot in cochlear explants treated 
















(A) Cell viabilities were measured using a CCK-8 assay in cells treated with 
various concentrations and combinations of cisplatin and Apelin (*P < 0.05, 
**P < 0.01,  ns P > 0.05), n=6. (B) Immunofluorescence staining of HCs 
labeled with Myosin 7a (green staining) in apical, middle and basal turns in 
control, Apelin-, cisplatin- and Apelin plus cisplatin-treated explants groups. 
(C-E) Total survival HCs counts in apical, middle and basal turns in control, 
Apelin-, cisplatin- and Apelin plus cisplatin-treated explants. (*P < 0.05, ns 













Figure 4 Apelin reduces cisplatin-induced apoptosis in HEI-OC1 cells  











Apelin plus cisplatin-treated cells. (B) Quantification of the proportion of 
apoptotic cells (gate%) in control, cisplatin- and Apelin plus cisplatin-treated 
cells. (C) TUNEL staining (green) in control, cisplatin- and apelin plus 
cisplatin-treated cells. (D) Quantification of the percentage of TUNEL-





Figure 5 Apelin protects mouse cochlear HCs from cisplatin-induced apoptosis  











explants in control, cisplatin- and Apelin- plus cisplatin-treated explants. (B) 
Quantification of TUNEL-positive cells in the middle turns of cochlear 
explants in control, cisplatin- and Apelin plus cisplatin-treated explants. (C) 
Quantification of apoptotic HCs co-stained by TUNEL/Myosinα in control, 
cisplatin- and Apelin plus cisplatin-treated explants. (D) Immunofluorescence 
staining of cleaved caspase-3 in the middle turns of control, cisplatin- and 
Apelin plus cisplatin-treated explants. (E) Quantification of cleaved caspase-
3-positive cells in control, cisplatin- and Apelin plus cisplatin-treated explants. 
(F) Quantification of apoptotic HCs co-stained by cleaved caspase-3/Myosin7














Figure 6 Apelin attenuates cisplatin-induced ROS and dysfunction of 
mitochondrial membrane potential in HEI-OC1 cells and cochlear explants 
(A) DCFH-DA staining, (B) ROS generation monitored by DCFH-DA and assayed 
by flow cytometry, (C) Mitosox-red staining and (D) ROS generation monitored 
by Mitosox-red assayed by flow cytometry in HEI-OC1 cells of control, 
cisplatin- and Apelin plus cisplatin-treated groups. (E) DCFH-DA staining and 
(F) Mitosox-red staining in cochlear explants of control, cisplatin- and Apelin 

























Figure 7 Apelin inhibits cisplatin-induced JNK signaling and caspase-dependent 
apoptosis in HEI-OC1 cells and cochlear explants 
(A, B) p-JNK levels were detected by western blot and analyzed in control, Apelin 
plus cisplatin- and cisplatin-treated HEI-OC1 cells. (C, D, E, F) The levels of cleaved 
caspase-3, cleaved caspase-9 and bax proteins were detected by western blot and 
analyzed in control, Apelin plus cisplatin- and cisplatin-treated HEI-OC1 cells. (G, H) 
The levels of p-JNK protein were determined by western blot and analyzed in control, 
Apelin plus cisplatin-treated and cisplatin-treated cochlear explants. (I, J, K, L) The 
levels of cleaved caspase-3, cleaved caspase-9 and bax proteins were analyzed by 
western blot in control, Apelin plus cisplatin- and cisplatin-treated cochlear explants. 
GAPDH and β-actin served as a loading control. (*p < 0.05, **p < 0.01). n=3. 
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